AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04375761 — intervention group
Intervention type: PROCEDURE
Intervention: Symptom and Exposure Surveys
Description: Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
Study NCT04379362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal laser ablation
Description: Focal laser ablation
Study NCT04370548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARE-BV1clindamycin phosphate vaginal gel, 2%
Description: One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
Study NCT04370548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DARE-BV1clindamycin phosphate vaginal gel, 2%
Description: One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
Study NCT02466750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Western Equine Encephalitis (WEE) Vaccine
Description: Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
Study NCT04261439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIZ985
Description: NIZ985 injection
Study NCT04261439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab infusion
Study NCT04261439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab infusion
Study NCT02905097 — intervention group
Intervention type: PROCEDURE
Intervention: Knee Replacement
Description: Surgical replacement of arthritic knee with an implant
Study NCT00074711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
Study NCT00074711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Phosphate
Description: Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
Study NCT03808116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartBx
Description: he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~* To preserve sample unity, including core fragments in their original location along the needle notch.~* Avoid sample damaging during sample removal from the needle and the following pathology process.
Study NCT04480489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR
Study NCT04480489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR
Study NCT04480489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR
Study NCT04480489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR
Study NCT03260881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide Pen Injector [Victoza]
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
Study NCT03260881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching liraglutide-placebo pre-filled pens
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
Study NCT02457390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CE-LUS
Description: To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure.
Study NCT01881191 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT02571712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03% plus timolol 0.5%
Description: 1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
Study NCT01809938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black tea
Description: 300ml of tea without milk
Study NCT01809938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tea with milk
Description: 250ml of black tea with 50ml of full fat milk
Study NCT03560882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablet, 80mg
Study NCT00297219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dialysate calcium
Description: 1.25 mmol/L dialysate calcium
Study NCT00297219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dialysate calcium
Description: 1.75 mmol/L dialysate calcium
Study NCT02910817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
Study NCT02910817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide gel
Description: 5% benzoyl peroxide in a gel applied topically once a day
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide gel
Description: 5% benzoyl peroxide in a gel applied topically once a day
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin gel
Description: 1% clindamycin phosphate applied topically once a day
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin gel
Description: 1% clindamycin phosphate applied topically once a day
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene cream
Description: 0.1 % tazarotene in a cream applied topically once a day
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene cream
Description: 0.1 % tazarotene in a cream applied topically once a day
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel is an identical gel without the active ingredients
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel is an identical gel without the active ingredients
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is an identical cream without the active ingredients
Study NCT00713609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is an identical cream without the active ingredients
Study NCT01917617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)
Description: Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively.
Study NCT01917617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine , Cisplatin
Description: Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more.
Study NCT00060528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-GM-CSF
Study NCT00060528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)
Study NCT00060528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)
Study NCT00060528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human GM-CSF
Study NCT01449162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: 6 mg/kg/day
Study NCT01449162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01274949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LI-ESWT
Description: Low intensity shock wave treatment - 12 sessions
Study NCT03188016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Interaction with Music
Description: Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
Study NCT03188016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intensive Interaction
Description: Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
Study NCT01166139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna)
Description: Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
Study NCT02587221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
Description: 1 dose approximately 0.5 mL of aQIV
Study NCT02587221 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Influenza Comparator (Boostrix)
Description: 1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
Study NCT00241384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation
Study NCT00241384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pd-103
Study NCT00499486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
Study NCT03028233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
Study NCT03028233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Parenting
Description: A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
Study NCT04477265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate 5mg/tab daily
Description: participants will be taking oral medication for 3 months
Study NCT04477265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5mg/tab daily
Description: participants will be taking oral medication for 3 months
Study NCT04477265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback-assisted pelvic floor muscle training
Description: participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
Study NCT04477265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback-assisted pelvic floor muscle training
Description: participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
Study NCT04730908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH
Study NCT04730908 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH
Study NCT04730908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH
Study NCT04730908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DENTIFRICE
Description: GEL -DENTIFRICE FOR BRUSHING TEETH
Study NCT05238077 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy
Description: Patients will have different kinds of light shined on different areas
Study NCT00771394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin hydrochloride
Description: oral
Study NCT00771394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Description: oral
Study NCT00771394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin hydrochloride
Description: oral
Study NCT00771394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral
Study NCT00771394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral
Study NCT01879111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-targeted feedback
Description: Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
Study NCT03383601 — intervention group
Intervention type: OTHER
Intervention: Heated Tobacco product IQOS/heatstick
Description: Heated Tobacco Products: heatsticks heated by iQOS device
Study NCT03383601 — intervention group
Intervention type: OTHER
Intervention: Smoking combustible cigarettes
Description: Current smoking of combustible cigarettes
Study NCT01277744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Peritoneal Perfusion (HIPEC)
Description: HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
Study NCT01277744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
Study NCT01140308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CoEnzyme Q10
Description: Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
Study NCT01140308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
Study NCT03688269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Description: Intravenous injection of 8mg/2ml dexamethasone
Study NCT03688269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline
Description: Intravenous injection of 2ml Saline 0.9%
Study NCT03688269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine
Description: Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
Study NCT03688269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perineural ropivacaine
Description: Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
Study NCT01622439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
Study NCT01622439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
Study NCT01622439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
Study NCT01622439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
Study NCT01622439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
Study NCT01622439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
Study NCT02065830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKSO
Description: The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training.
Study NCT04506840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
Study NCT01723241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5, concentration A
Study NCT00903604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP214
Description: Three 10-minutes infusions of sequential ascending dosages of AP214
Study NCT00903604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three 10-minutes infusions of isotonic saline solution
Study NCT01723241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5, concentration B
Study NCT01723241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5, concentration C
Study NCT01723241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo